ADAM17 and Insulin resistance: Similarly, the activity of ADAM17, also known as TNF-α converting enzyme (TACE), correlates with insulin resistance [8, 9] and administration of TACE inhibitors to humans in clinical trial settings has proven to effectively decrease inflammatory mediators [10].